Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Launched by GLAXOSMITHKLINE · Jun 9, 2006
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A male or female aged 4 to 6 years at the time of study entry .
- • Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine in previous vaccination studies.
- • Evidence of previous hepatitis B booster vaccination or disease since administration of the fourth dose of DTPa-HBV-IPV/Hib vaccine.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salzgitter, Niedersachsen, Germany
Erkrath, Nordrhein Westfalen, Germany
Husum, Schleswig Holstein, Germany
Muenchen, Bayern, Germany
Trier, Rheinland Pfalz, Germany
Muenchen, Bayern, Germany
Offenburg, Baden Wuerttemberg, Germany
Stuttgart, Baden Wuerttemberg, Germany
Noerdlingen, Bayern, Germany
Tutzing, Bayern, Germany
Weilheim, Bayern, Germany
Trier, Rheinland Pfalz, Germany
Berlin, , Germany
Cham, Bayern, Germany
Krefeld, Nordrhein Westfalen, Germany
Willich, Nordrhein Westfalen, Germany
Bad Saulgau, Baden Wuerttemberg, Germany
Boennigheim, Baden Wuerttemberg, Germany
Kehl, Baden Wuerttemberg, Germany
Oberkirch, Baden Wuerttemberg, Germany
Schwaebisch Hall, Baden Wuerttemberg, Germany
Kleve Materborn, Nordrhein Westfalen, Germany
Flensburg, Schleswig Holstein, Germany
Ettenheim, Baden Wuerttemberg, Germany
Waren, Mecklenburg Vorpommern, Germany
Heiligenhaus, Nordrhein Westfalen, Germany
Bredstedt, Schleswig Holstein, Germany
Kaufering, Bayern, Germany
Freising, Bayern, Germany
Schoeneberg Kuebelberg, Rheinland Pfalz, Germany
Landsberg, Bayern, Germany
Berlin, , Germany
Tuttlingen, Baden Wuerttemberg, Germany
Altenholz, Schleswig Holstein, Germany
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials